Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Edgewise Therapeutics Shares Surge 15% to $39.40 on Promising Muscle Disease Treatment Data

Published

on

Edgewise Therapeutics (EWTX) Explodes 23% on Pipeline Momentum and Strong

NEW YORK — Edgewise Therapeutics Inc. shares climbed 15.38 percent to $39.40 in morning trading on Monday, June 1, 2026, as investors responded to encouraging clinical progress in the company’s pipeline of precision medicines for rare muscle disorders and broader positive sentiment in the biotechnology sector.

The sharp gain pushed Edgewise’s market capitalization significantly higher and reflected growing confidence in its scientific platform targeting serious neuromuscular conditions with limited treatment options. Trading volume surged well above average levels as the stock drew attention from both institutional investors and retail traders.

Edgewise Therapeutics specializes in developing therapies that address the underlying mechanisms of muscle diseases rather than merely treating symptoms. The company’s approach emphasizes precision pharmacology to restore muscle function while minimizing side effects, a strategy that has resonated with investors seeking exposure to innovative rare disease treatments.

Clinical Momentum Fuels Optimism

Recent data from Edgewise’s ongoing clinical programs have shown promising safety and efficacy signals in mid-stage studies. The company’s lead candidate has demonstrated encouraging results in patients with conditions such as Duchenne muscular dystrophy and other rare myopathies. These early findings have increased expectations for potential accelerated development paths and future regulatory milestones.

Advertisement

Analysts have highlighted Edgewise’s differentiated science as a key driver of today’s move. The company’s focus on muscle biology has positioned it within a niche that has seen heightened interest from both investors and larger pharmaceutical companies looking to expand their rare disease portfolios. Positive data presentations at recent medical conferences have further supported the bullish sentiment.

The surge also comes amid a broader recovery in biotechnology valuations. After a period of sector-wide pressure, investors have shown renewed appetite for companies with strong clinical pipelines and clear paths to addressing significant unmet medical needs. Edgewise has benefited from this improved environment, standing out even within a stronger biotech group.

Company Background and Development Strategy

Edgewise Therapeutics was founded to advance novel treatments for muscle-related disorders through a precision medicine platform. The company has built a focused pipeline targeting rare neuromuscular conditions that affect both children and adults. Its lead programs have progressed through early clinical stages with encouraging biomarker and functional data.

The company maintains a disciplined approach to capital allocation, advancing its most promising candidates while preserving financial flexibility. Edgewise has successfully raised capital through public offerings and strategic partnerships, providing sufficient runway for its current development activities. Management has emphasized scientific rigor and close collaboration with patient advocacy groups to ensure research aligns with real-world clinical needs.

Advertisement

Edgewise’s platform technology aims to modulate muscle function at the molecular level, potentially offering advantages over existing therapies. The company continues to invest in expanding its intellectual property portfolio and optimizing manufacturing processes to support future commercialization efforts.

Analyst Perspectives and Valuation Considerations

Wall Street analysts have largely responded positively to Edgewise’s recent progress. Most firms covering the stock maintain Buy or Outperform ratings, citing the substantial market opportunities in rare muscle disorders and the company’s competitive differentiation. Average price targets have trended higher, with some optimistic forecasts projecting meaningful upside if late-stage data continues to support advancement.

However, analysts also emphasize the inherent risks in clinical-stage biotechnology. Drug development carries high attrition rates, and regulatory pathways for rare disease treatments, while sometimes offering expedited review, still require robust evidence of benefit. Edgewise will need consistent results in larger trials to sustain current valuations and justify further investment.

The stock’s valuation, while elevated following today’s surge, remains within ranges considered reasonable for a clinical-stage company with differentiated assets and a strong cash position. Edgewise’s financial runway reduces near-term dilution concerns, though additional capital may be required as programs advance toward pivotal studies.

Advertisement

Sector Trends and Competitive Landscape

The rare disease therapeutics space has attracted increased attention in 2026 as advances in genetic understanding and precision medicine open new treatment possibilities. Edgewise operates in a competitive but high-potential field where successful therapies can command premium pricing and generate significant revenue due to limited patient populations and high unmet need.

Larger pharmaceutical companies have shown interest in acquiring or partnering with innovative biotech firms in the muscle disease area. Edgewise’s progress could position it as an attractive collaboration candidate, potentially providing validation and resources for late-stage development.

Broader market sentiment toward biotechnology has improved with moderating interest rates and renewed investor appetite for innovation-driven growth stories. This environment has been supportive for companies like Edgewise with clear scientific theses and advancing clinical programs.

Risks and Challenges Facing Edgewise

Despite today’s strong performance, Edgewise faces typical biotech development risks. Clinical trial outcomes can be unpredictable, and larger studies may not replicate early positive signals. Manufacturing scalability, intellectual property protection and eventual commercialization strategies will become increasingly important as programs mature.

Advertisement

Competition in the muscle disease space is intensifying, with several companies pursuing similar or complementary approaches. Regulatory requirements, while sometimes offering accelerated pathways for rare diseases, still demand comprehensive safety and efficacy data. Edgewise must navigate these challenges while managing its cash position efficiently.

Market volatility remains a significant factor for smaller biotechnology companies. Share prices can experience sharp reversals on clinical news, regulatory updates or broader sector rotations. Investors should approach positions with appropriate risk management and diversification.

Investment Considerations for 2026

Investors considering Edgewise Therapeutics should weigh its innovative platform and clinical momentum against the uncertainties of drug development. The company may appeal to those with conviction in its science and tolerance for volatility typical of clinical-stage biotechs. However, position sizing should remain modest given the binary nature of clinical outcomes.

Longer-term investors may focus on upcoming clinical milestones, regulatory interactions and potential partnership announcements. Near-term traders might monitor technical levels and news flow for additional momentum opportunities. Professional financial advice tailored to individual risk tolerance and investment objectives is recommended before taking positions in the biotechnology sector.

Advertisement

Today’s substantial gain in Edgewise shares underscores investor enthusiasm for companies advancing promising treatments for rare and debilitating conditions. As the company progresses through its clinical programs, it remains one of the more closely watched names in the muscle disease therapeutics space.

Market participants will monitor future data readouts and corporate developments for further signals about Edgewise’s trajectory. The biotechnology sector in 2026 is likely to feature both significant winners and disappointments, with companies demonstrating strong execution and scientific differentiation best positioned for success.

For now, Edgewise Therapeutics’ performance on the first trading day of June reflects growing optimism about its potential to address significant unmet needs in muscle disorders. Whether this momentum continues will depend on sustained clinical success and favorable regulatory developments in the months ahead.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Morgan Stanley to open its wealth management funnel to agents

Published

on

Morgan Stanley to open its wealth management funnel to agents

Morgan Stanley’s office in Canary Wharf financial district on Jan. 30, 2025 in London, UK.

Mike Kemp | In Pictures | Getty Images

Morgan Stanley will soon open a key wealth management funnel to artificial intelligence agents from thousands of corporations, CNBC has learned exclusively. It’s one of the earliest instances of a major Wall Street bank opening its platforms to external AI tools.

Advertisement

The move will allow clients’ autonomous agents to pull data and insights directly from the firm’s stock administration platforms, ShareWorks and Equity Edge, bypassing the traditional software interfaces built for human users, according to Mark Mitchell, chief product officer of Morgan Stanley at Work.

In April, Morgan Stanley executives attributed $1.2 trillion in assets gathered to its workplace strategy.

“The way we see it, in a future state, our corporate clients will not be logging into ShareWorks or Equity Edge,” Mitchell said.

Instead, they’ll be “using agentic AI-powered tools on their desktops within the four walls of their companies, interacting with our platforms in a purely agentic way,” he said.

Advertisement

The bank has already granted a handful of clients early agentic access and plans to open it up to the firm’s 3,400 administration clients by next year, Mitchell said.

It’s the latest sign that Wall Street is preparing for a future where AI agents handle tasks now performed by software users.

Rivals including JPMorgan Chase and Goldman Sachs are using AI agents internally for things like writing code, but have yet to publicly announce steps to allow external agents to connect directly to their firms’ systems.

Morgan Stanley wealth management

Morgan Stanley has taken the staid business of managing stock compensation plans for corporations and turned it into a crucial funnel for the firm’s wealth management division, which is the world’s largest at $7.35 trillion in client assets.

Advertisement

The firm acquired Solium Capital in 2019 and E-Trade in 2020, creating a business that it says caters to almost half of the companies in the S&P 500 and eight of the 10 biggest unicorn startups. The key insight it had was that by administering employee stock plans, Morgan Stanley can convert workers into advisory clients as their wealth grows.

The bank’s AI pitch to corporate clients is straightforward: Fast-growing technology and biotech companies want to administer increasingly complex stock plans without adding headcount in support roles like human resources, said Mitchell.

At these companies, AI agents can handle aspects of the job without adding human employees, he said.

Internally, there’s a similar logic: Morgan Stanley sees agentic AI allowing it to scale its own services — customer support, plan administration, the wealth management funnel — without adding “thousands and thousands” of employees, Mitchell said.

Advertisement

For this change, Morgan Stanley is leaning on something called the Model Context Protocol, an open source standard that allows AI models to plug into data sources.

In a pre-AI world, companies would’ve frowned upon allowing clients to bypass the online front door to their services. For decades, companies fought to hook users on proprietary platforms.

Morgan Stanley, which began partnering with OpenAI in 2022, believes that matters less in a world where AI agents become the primary interface. Software is “at an inflection point, clearly,” Mitchell said.

“The companies that are going to survive in the future are the ones who have proprietary data and business logic, which is the foundation of our offering,” Mitchell said.

Advertisement

“The fact that they won’t be logging into” the websites, he said, “doesn’t scare us at all.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Miller Industries: Even With Growth On The Horizon, Conditions Justify Caution (NYSE:MLR)

Published

on

Miller Industries: Even With Growth On The Horizon, Conditions Justify Caution (NYSE:MLR)

This article was written by

Daniel is an avid and active professional investor.
He runs Crude Value Insights, a value-oriented newsletter aimed at analyzing the cash flows and assessing the value of companies in the oil and gas space. His primary focus is on finding businesses that are trading at a significant discount to their intrinsic value by employing a combination of Benjamin Graham’s investment philosophy and a contrarian approach to the market and the securities therein. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Universal Corp: The Three Reasons Why I Am Downgrading To Hold

Published

on

Woman holding regular, electronic cigarette and disposable vape on white background. Tobacco heating systems.

Universal Corp: The Three Reasons Why I Am Downgrading To Hold

Continue Reading

Business

Established SMEs play a key role in Welsh private sector employment

Published

on

Business Live

New research on their impact has been carried out by Oxford Economics on behalf of Allica Bank

Conrad Ford chief product and strategy Officer at Allica Bank.

Established SMEs in Wales out punch their weight in terms of their contribution to jobs in the Welsh economy, show new research.

A report , carried out by Oxford Economics on behalf of Allica Bank, shows that established businesses account for over two in five jobs in the private sector despite making up just 22.8% of the Wales’ business population.

Advertisement

Established SMEs are firms with between five and 250 employees – of which in Wales there are 23,965.

Their contribution of 44% of all private sector jobs in Wales, is nine percentage points above the UK average of 35%, and significantly higher than London, where established businesses account for 30% of private sector employment. Of the nations and regions of the UK, the rate is only higher in Northern Ireland at 46%

Across the UK, established businesses are a critical driver of economic activity, accounting for more than a third of private sector employment and 37% of private sector turnover. They also support almost one in every two private sector jobs in rural areas.

Given their importance to growth, the report also highlights the challenge many established businesses face in accessing the finance they need to invest. The report highlights a £65bn lending gap to UK SMEs, accumulated over the past 25 years, which is restricting the finance and working capital available to businesses that want to expand, boost productivity and create jobs.

Advertisement

It also shows the impact that can be unlocked when established businesses can access the finance they need. In 2025, Allica Bank’s lending to established businesses enabled an estimated £520m contribution to GDP in Wales and supported 8,700 jobs locally.

UK-wide, 78% of the GDP contribution and 80% of the employment impact supported by Allica Bank’s lending occurred outside London and the south east, underlining the role productive finance can play in supporting local economies.

Conrad Ford, chief product and strategy officer at Allica Bank, said:“I speak to established businesses all the time and you quickly see how important they are to their local areas. These are the manufacturers, logistics firms, hospitality operators and specialist businesses that employ local people, support supply chains and keep communities thriving.

“The report puts numbers behind that. Although established businesses make up a minority of the wider SME business population, they account for around 60% of private sector employment.

Advertisement

“In 2025, Allica Bank’s lending to established businesses enabled an estimated £8.4 billion contribution to GDP in the UK and supported 118,000 jobs across the country. That shows what can happen when established businesses get the finance they need to invest and grow.”

Continue Reading

Business

Lloyds, Halifax and Bank of Scotland app users hit by outage

Published

on

Lloyds, Halifax and Bank of Scotland app users hit by outage

“We’re aware some customers are having issues with our app and online banking. We’re really sorry about this,” Lloyds Bank posted on X.

Continue Reading

Business

Library building in Brecon transformed into a new learning campus

Published

on

Business Live

The £6m project was carried out by Swansea-based Andrew Scott

The repurposed Ship Street Library building in Brecon.(Image: Phil Boorman Photography Ltd)

Work on a £6m project repurposing a listed building that served as a library in Brecon into a new learning campus has been completed.

Contractors Andrew Scott carried out the work on the Ship Street Library building on behalf of NPTC Group of Colleges.

Advertisement

The refurbishment and retrofit marks the next chapter in both the building’s history and the college’s development. By relocating a significant portion of its Brecon campus to a central town location, NPTC Group of Colleges aims to improve accessibility for students

The project is also expected to strengthen links with the local community and increase footfall in Brecon town centre. The building has been intentionally designed without canteen facilities to encourage students to make use of town centre amenities and support local businesses.

Inside the building.(Image: Phil Boorman Photography Ltd)

Designed by Rio Architects, the building now provides ten general teaching classrooms, student support and welfare spaces, staff areas, social learning zones, and four start-up business units, alongside a new lift to improve access.

Mark Bowen, managing director of Swansea-based Andrew Scott, said: “We are delighted to have completed the renovation and enhancement of the grade II listed Ship Street Library.

Advertisement

“This project has provided an opportunity to preserve a much-loved historic building while creating an inspiring and accessible learning environment for students and the wider community. We hope the revitalised space will strengthen local connections, support nearby businesses and inspire the next generation of learners.”

The library was originally designed by the County Architects Department under the direction of county architect JA McRobbie. It was officially opened by the then Prince of Wales in 1969 and is considered a significant example of post-war architecture of national importance.

NPTC Group of Colleges works in partnership with Coleg Sir Gâr, Coleg Ceredigion, Cardiff and Vale College, and Pembrokeshire College to develop higher technical education and employer-led training and innovation.

Advertisement
Continue Reading

Business

ADP National Employment report May 2026: Private sector adds 122,000 jobs

Published

on

ADP National Employment report May 2026: Private sector adds 122,000 jobs

This is a breaking news story about the ADP national employment report for May. Please check back for updates.

Companies in the private sector added 122,000 jobs in May, payroll processing firm ADP said in its latest report on Wednesday.

Advertisement

The figure is above economists’ estimates of a gain of 117,000 jobs. The prior month’s payrolls number was revised lower to a gain of 105,000 from an initially reported gain of 109,000.

TOP CEOS BRACE FOR DOWNTURN, WARN US ECONOMY WILL WORSEN IN NEXT 6 MONTHS

Elementary school educators in Maryland

ADP released data from its May National Employment report on Wednesday. (Amanda Andrade-Rhoades/For The Washington Post via Getty Images)

HOW AI EXPOSURE IS RESHAPING JOBS IN CREATIVE FIELDS

Which industries are hiring the most workers, according to the ADP report?

What experts are saying about the ADP report data

The ADP data is released before the Labor Department’s nonfarm payrolls report, which is due on Friday morning and can differ notably. The government data is expected to show an increase of 85,000 positions, below the 115,000 reported in April.

Advertisement
Continue Reading

Business

NorthStandard reports solid results despite global risks on the rise

Published

on

Business Live

The marine insurance mutual saw premium income grow substantially to $938m (£697.1m)

NorthStandard managing directors Paul Jennings (left) and Jeremy Grose

NorthStandard managing directors Paul Jennings (left) and Jeremy Grose(Image: GRAHAM FLACK)

Conflicts in the Middle East, Persian Gulf and Ukraine are creating a more challenging world for shipowners, one of world’s largest insurers in the sector has said. Tyneside-based NorthStandard says changing tariffs and expansion of sanctions have created uncertainty in the global market.

It comes as the Newcastle-based mutual has published what it called strong results showing a 5.8% lift in premium income to US$938m (£697.1m) in its 2025/26 year with an underwriting deficit reduced from $96m (£71.3m) to $39m (£28.9m). The provider of third party liability and related cover to shipowners and operators also reported $123m (£91.4m) growth in free reserves to $923m (£686.2m).

Writing in the membership group’s annual review, NorthStandard chairman Cesare d’Amico said: “Conflict in the Middle East from Gaza to the Persian Gulf, the continuation of the war in Ukraine, the uncertainty caused by changing tariffs, and the steady expansion of sanctions regimes all combined to undermine predictability in trade, compliance and insurance. Shipowners faced higher costs, greater operational disruption and a more complex liability landscape, often driven by events entirely outside their control.”

It is now three years since the merger of Newcastle’s North P&I and London-based The Standard Club to create NorthStandard, which is one of the top global marine insurance providers with offices in Europe, Asia and the Americas. The firm employs about 300 people on Tyneside.

Advertisement

Bosses said the objectives of that merger had now been met, including development of specialty lines, opening of new offices, expanded resources and new partnerships to benefit members. Since the merger, growing geopolitical instability – notably events in the Strait of Hormuz – has rocked the shipping world, with NorthStandard saying it has provided vast amounts of guidance to members, particularly around war risks.

And on sanctions, the club said it has invested to create a stronger service for members including the appointment of a head of sanctions who operates on a global level from the Newcastle offices.

During the year, NorthStandard also consolidated its Coastal & Inland and Sunderland Marine teams under one leadership, offering a ‘one stop shop’ for small and specialist craft. It also set up an Upstream Energy and Marine & Energy Liabilities team to target those markets.

Jeremy Grose, NorthStandard managing director, said: “The shipping industry is navigating profound change, as technological advancement and the fuel transition reshape how vessels are operated, crewed, and maintained. Our services are evolving in step, ensuring Members can adopt new fuels, technologies, and operating models with confidence.

Advertisement

Fellow managing director, Paul Jennings, added: “People are our biggest strength, and our strong performance is a direct reflection of their dedication—many of whom are based right here at our headquarters in the North East. We remain deeply committed to supporting our communities, economy, and environment through strategic, long-term collaboration and investing in our people and innovation”.

Continue Reading

Business

Poland’s Breakthrough Star at Roland Garros 2026

Published

on

Elina Svitolina
Maja Chwalińska
Maja Chwalińska

Maja Chwalińska, the 24-year-old Polish left-hander ranked outside the top 100 at the start of the 2026 French Open, has captured global attention with a remarkable run to the quarterfinals at Roland Garros, emerging as one of the biggest Cinderella stories of the tournament.

Chwalińska’s journey from qualifier to quarterfinalist, defeating high-profile opponents including Olympic champion Qinwen Zheng and former top-10 player Maria Sakkari, highlights her resilience and talent. Her story combines athletic achievement with personal challenges, making her one of the most compelling figures in women’s tennis this season.

Here are 10 essential things to know about the rising Polish player:

1. Rapid Rise at Roland Garros 2026 Chwalińska entered the 2026 French Open as a qualifier ranked around No. 114. She stormed through the qualifying rounds and main draw with dominant performances, reaching the quarterfinals after victories over Zheng, Elise Mertens, Sakkari and Diane Parry. Her run marked the first time a player ranked outside the top 100 achieved such a deep breakthrough at Roland Garros in recent memory.

2. Career-High Ranking and Momentum The Polish player achieved a career-high singles ranking of No. 113 in May 2026. Her French Open success is projected to propel her significantly higher, potentially into the top 50. This surge reflects strong form on the WTA 125 and ITF circuits, where she captured multiple titles.

Advertisement

3. Left-Handed Game with Technical Precision Standing at 5-foot-5 (1.64 m), Chwalińska plays left-handed with a two-handed backhand. Observers praise her clean technique, variety, and court craft. Analysts describe her style as old-school with modern efficiency, generating consistent pressure on return games while maintaining solid baseline rallies.

4. Early Start and Polish Roots Born on October 11, 2001, in Dąbrowa Górnicza, Poland, Chwalińska began playing tennis at age 7. She turned professional in 2015-2016 and has remained based in her home country, representing Poland in Fed Cup/Billie Jean King Cup competition with a solid 4-3 record.

5. Openness About Mental Health Struggles Chwalińska has been candid about her battle with depression, which sidelined her for periods and affected her early career progression. Her willingness to discuss mental health has resonated with fans and fellow athletes, positioning her as an advocate for greater awareness in professional sports.

6. Strong Challenger and ITF Success Before her Grand Slam breakthrough, Chwalińska built her career through consistent performances on the ITF and WTA 125 circuits. She has won three WTA Challenger singles titles, including events in Montreux (2025) and Florianopolis (2024), along with seven ITF singles titles.

Advertisement

7. Doubles Expertise In addition to singles, Chwalińska has enjoyed success in doubles, with a career-high ranking of No. 91. She has secured three WTA 125 doubles titles, demonstrating versatility and strong net play that complements her baseline game.

8. Coaching Stability She is coached by Jaroslav Machovsky, who has helped guide her technical development and mental approach. Their partnership has been credited with her recent consistency and ability to perform under pressure at major tournaments.

9. Historic Polish Representation Chwalińska’s deep run at Roland Garros 2026 made her the second Polish woman, alongside world No. 3 Iga Świątek, to reach the fourth round in the same year. This milestone underscores the growing strength of Polish women’s tennis on the international stage.

10. Humble Personality and Future Ambitions Known for her humble and grounded demeanor, Chwalińska expressed surprise and gratitude during her French Open press conferences. She stated her seasonal goal was simply to break into the top 100, a target she has now surpassed. Fans and commentators highlight her likeable character and work ethic as key factors in her appeal.

Advertisement

Chwalińska’s prize money has surpassed $860,000 in her career, with a significant boost expected from her Paris performance. Her story echoes previous Grand Slam underdog runs, drawing comparisons to players who used breakthrough tournaments to launch sustained top-level careers.

The left-hander’s success comes after years of grinding on lower circuits while managing personal challenges. Her mental health advocacy adds depth to her profile, showing strength beyond on-court results. As she faces higher-ranked opponents in the quarterfinals and beyond, Chwalińska’s composure and fighting spirit will be tested.

Tennis experts note her well-rounded game suits clay courts particularly well, where her patience and tactical awareness shine. If she maintains this level, a top-50 breakthrough appears likely, with potential for further Grand Slam success in the coming seasons.

Poland’s tennis federation and fans have rallied behind Chwalińska, celebrating her as a fresh talent alongside established stars like Świątek. Her run has boosted national pride and inspired younger players in the country’s growing tennis community.

Advertisement

As the 2026 season progresses, Chwalińska’s focus will shift toward consistency at the tour level. Sustaining momentum after a major deep run often presents challenges, but her proven resilience suggests she is prepared for the next steps in her career.

Chwalińska represents the new generation of Polish tennis talent — technically sound, mentally tough, and authentically connected with supporters. Her breakthrough at Roland Garros serves as a reminder that perseverance and belief can overcome ranking disadvantages on tennis’s grandest stages.

With several years ahead in her prime, the tennis world will watch closely to see how far this late-blooming star can climb. For now, her magical run in Paris has already secured her place among the memorable stories of 2026.

Advertisement
Continue Reading

Business

Ampol's $1.1b EG acquisition approved

Published

on

Ampol's $1.1b EG acquisition approved

Ampol will have to sell 41 petrol stations to Metro Petroleum as a condition of the ACCC’s approval of its $1.1 billion acquisition of EG Australia and its over 500 sites.

Continue Reading

Trending

Copyright © 2025